iBio’s fiscal 2026 Revenue fell $0.3 million to approximately $0.1 million, while R&D expense rose approximately $11.3 million to $19.6 million. Investors also have a reported $88.0 million in cash and Debt securities, and management says financings extend the cash runway into fiscal year 2028.

Key Highlights

  • IBio held approximately $88.0 million in cash and investments in debt securities as of June 30, 2026.
  • A $5.0 million Impairment charge was recorded against an indefinite-lived intangible asset.
  • IBio reported a net loss of $33.044 million for the fiscal year.

Research and development spending rose approximately $11.3 million to $19.6 million, reflecting higher Investment in the company’s development programs.

Operating Costs Expand

Research and development expenses reached approximately $19.6 million, compared with $8.3 million in the comparable fiscal year. IBio attributed the increase mainly to approximately $8.4 million of additional spending on consultants and outside services supporting its R&D efforts, including work connected with IBIO-610, IBIO-600 and other preclinical pipeline assets.

A $2.5 million development milestone also contributed to the increase. General and administrative expenses moved in the opposite direction, declining approximately $0.1 million to $10.6 million from $10.7 million.

The company recorded approximately $5.0 million of impairment tied to its indefinite-lived IBIO-101 intangible asset.

Loss Reaches $33.044 Million

IBio reported a net loss of $33.044 million for the fiscal year, compared with $18.377 million in the prior fiscal year. Revenue was approximately $0.1 million for the period, down from $0.4 million.

Capital Supports Development

IBio held approximately $88.0 million in cash and cash equivalents plus investments in debt securities as of June 30, 2026. A $26 million private Placement was also completed with healthcare-focused institutional investors. Management said the financings extended iBio (NASDAQ: IBIO)’s cash runway into fiscal year 2028.

Pipeline Moves Toward Clinical Work

IBIO-610 advanced into IND-enabling studies, with preclinical work assessing fat-selective weight loss, combination effects with semaglutide and weight regain after GLP-1 discontinuation.

IBIO-800 entered IND-enabling development after selection of a development candidate. The company also in-licensed AstralBio’s amylin receptor antibody program, whose candidates are undergoing preclinical characterization for obesity and metabolic disease.

Elizabeth Stoner, M.D. Joined the Board, while Molly Carr, M.D. Became Chief Medical Officer.